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SH-SY5Y cellThe major human tyrosine hydroxylase isoforms (hTH1 and 2) differ in their ability to be phosphorylated in
vitro. hTH1 is phosphorylated at Ser31 by extracellular signal-regulated kinase (ERK). This kinase is not
capable of phosphorylating hTH2 at Ser35 (the residue that corresponds to Ser31 in hTH1). We have stably
transfected SH-SY5Y cells with hTH1 or hTH2 to determine if hTH2 can be phosphorylated at Ser35 in situ.
Forskolin increased the phosphorylation of Ser40 in hTH1 and Ser44 in hTH2. Muscarine increased the
phosphorylation of both Ser19 and Ser40/44 in both hTH1 and hTH2. EGF increased the phosphorylation of
Ser31 in hTH1. Phosphorylation of Ser35 in hTH2 was not detected under any of the conditions tested.
Inhibition of ERK by UO126 decreased the phosphorylation of Ser31 and this lead to a 50% decrease in the
basal level of phosphorylation of Ser40 in hTH1. The basal level of Ser44 phosphorylation in hTH2 was not
altered by treatment with UO126. Therefore, phosphorylation of Ser31 contributes to the phosphorylation of
Ser40 in hTH1 in situ; however, this effect is absent in hTH2. This represents a major difference between the
two human TH isoforms, and has implications for the regulation of catecholamine synthesis in vivo.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Tyrosine hydroxylase (TH) [EC1.14.16.2], the rate-limiting enzyme
in catecholamine biosynthesis [1], is subject to a wide variety of
regulatory mechanisms [2]. Long-term regulation of TH activity is
primarily controlled by modulation of TH protein levels [2]. Acute
regulation of TH activity occurs via two distinct forms of feedback
inhibition by the catecholamines [3] and also by phosphorylation of
three key serine (Ser) residues: Ser19, Ser31 and Ser40 [4].
The binding of catecholamines to TH results in a 78–98% inhibition
of enzyme activity in vitro [3]. Phosphorylation of Ser40 directly
increases TH activity by inducing a 500-fold increase in the rate of
dissociation of the catecholamines from the high afﬁnity site of TH [5],
thereby relieving catecholamine inhibition of the enzyme [6].
Stimulation of Ser40 phosphorylation results in an increase in TH
activity and catecholamine synthesis in situ and in vivo [4]. While the
role of phosphorylation of Ser40 is well-understood, the function of
phosphorylation of Ser19 and Ser31 has only recently been elucidated.
Phosphorylation of Ser19 does not directly increase TH activity in
vitro [7]; however, incubation of Ser19-phosphorylated THwith 14-3-
3 protein is able to produce a small increase in enzyme activity [8,9].rine; hTH, human TH; BH4,
ted protein kinase; CaMKII,
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activity in vitro, primarily by decreasing the KM for the cosubstrate
tetrahydrobiopterin (BH4) [10,11]. In addition to these small effects
on TH activity, prior phosphorylation of Ser19 or Ser31 is able to
increase the rate of phosphorylation of Ser40 by approximately 3-fold
and 9-fold, respectively, in vitro in a process known as hierarchical
phosphorylation [12,13]. Phosphorylation of Ser19 or Ser31 potenti-
ates both the phosphorylation of Ser40 and the pSer40-induced
increase in TH activity in situ [13,14].
TH is encoded by a single gene. While most species express only a
single isoform of TH [15], there are 4 human TH (hTH) isoforms
(hTH1-4) which differ only in the number of amino acids N-terminal
to the Ser31 residue in hTH1 [16,17]. The sequence surrounding the
other phosphorylation sites is identical in all TH isoforms. hTH1 is the
smallest of the hTH enzymes, and is homologous to TH found in other
species [18]. hTH2 contains an additional 4 amino acids inserted
immediately N-terminal to Ser31, hTH3 contains an additional 24
amino acids, while hTH4 contains both inserts (4+27). All four
isoforms are expressed in human brain and adrenals [19,20], with
hTH1 and hTH2 being the two major isoforms, together comprising
approximately 90% of TH in brain [20,21].
hTH1 is phosphorylated at Ser31 in vitro by extracellular signal-
regulated protein kinase (ERK) [11,13]; however, hTH2 cannot be
phosphorylated at the equivalent Ser31 residue (Ser35) by ERK
[11,13]. The addition of four amino acids N-terminal to this residue in
hTH2 was believed to change the kinase speciﬁcity of the site from an
ERK site to a calcium/calmodulin-dependent protein kinase II
(CaMKII) site [22]. However, in other studies CaMKII was unable to
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whether hTH2 can be phosphorylated at Ser35 in intact systems.
Due to the important role that phosphorylation of Ser31 plays in
regulating the rate of Ser40 phosphorylation, the absence of
phosphorylation of Ser35 in hTH2 represents a major difference
between the two isoforms [13]. We have stably transfected the
neuroblastoma cell line SH-SY5Y with hTH1 and hTH2 isoforms and
stimulated the cells in an effort to determine whether hTH2 is able to
be phosphorylated at Ser35 in situ and investigate the inﬂuence that
this may have on differential regulation of the two isoforms in situ.
2. Materials and methods
2.1. Materials
pcDNA3.1, Lipofectamine 2000 and geneticinwere from Invitrogen
(Carlsbad, CA, USA). Wizard SV gel and PCR clean-up system and
UO126 were from Promega (Madison, WI, USA). XL1-blue competent
cells were from Stratagene (La Jolla, CA, USA). Quicklyse plasmid
puriﬁcation mini-prep kit and plasmid puriﬁcation maxi-prep kit
were from Qiagen (Hilden, Germany). SH-SY5Y cells were obtained
from ATCC (Manassas, VA, USA). Dulbecco's Modiﬁed Eagle Medium
(DMEM) was from GIBCO (Carlsbad, CA, USA). Fetal calf serum was
from Bovogen (Essendon, Australia). Rat-tail collagen, forskolin,
muscarine chloride and mouse anti-β-actin antibody were from
Sigma-Aldrich (St Louise, MO, USA). Epidermal growth factor was
from Afﬁnity BioReagents (Golden, CO, USA). L-[3,5-3H]-tyrosine was
from GE Healthcare (Buckinghamshire, England). Peptides were
synthesized by Auspep (Parkville, Australia). Sulfolink immobilization
kit and Aminolink plus immobilization kit were from Pierce (Rock-
ford, IL, USA).
2.2. Preparation of pcDNA3.1 hTH1 and hTH2
pcDNA3.1 hTH1 was generously supplied by Ingo Lehmann. For
pcDNA3.1 hTH2, hTH2 cDNA was ampliﬁed from pET3a hTH2 by PCR
using primers constructed to encompass the BamHI and EcoRI sites
(forward primer=CGTAGGATCCATGCCCACCCCCGACGCAACC, re-
verse primer=CGTAGAATTCCTAGCCAATGGCACTCAGCGC). The PCR
product was puriﬁed using the Wizard SV gel and PCR clean-up
system according to the manufacturer's instructions. The puriﬁed PCR
product and pcDNA3.1 were digested with BamHI and EcoRI, and then
puriﬁed using the Wizard SV gel and PCR clean-up system. The
puriﬁed hTH2 and pcDNA3.1 digests were then ligated together, and
transformed into XL1-Blue competent cells. Transformed bacteria
were selected using LB agar plates containing 100 μg/mL ampicillin.
Overnight cultures were inoculated from single colonies, and
plasmids puriﬁed using the Quicklyse plasmidmini-prep kit according
to the manufacturer's instructions. Insertion of hTH2 cDNA into
pcDNA3.1 was conﬁrmed by DNA sequencing.
Stocks of pcDNA hTH1 and pcDNA hTH2 were prepared using the
plasmid puriﬁcation maxi-prep kit according to the manufacturer's
instructions, and were stored at −20 °C in DNAse/RNAse-free H2O.
2.3. Cell culture
Transfected and wild-type SH-SY5Y cells were routinely main-
tained in 10% DMEM (DMEM supplemented with 10% fetal calf serum,
10mMHepes and 2mM L-Glutamine) at 37 °C, 5% CO2 in a humidiﬁed
incubator. Cells were not allowed to exceed 90% conﬂuency before
passaging, and were not used above passage 20.
6-well and 12-well plates were coated with 10 μg/mL rat-tail
collagen in phosphate-buffered saline for 2 h at 37 °C, and then
washed with phosphate-buffered saline, prior to plating of cells. Cells
were plated in collagen-coated plates (unless otherwise stated) at a
density of 4–7×105 cells/well for 6-well plates, and 2–4×105 cells/well for 12-well plates, and were maintained in 10% DMEM until 80%
conﬂuent.
2.4. Stable transfection of SH-SY5Y cells
SH-SY5Y cells were plated in 12-well (non collagen-coated) plates
at a density of 4×105 cells/well, and were incubated with 1.6 μg
pcDNA3.1 hTH1 or pcDNA3.1 hTH2 and 4 μL Lipofectamine 2000
reagent for 24 h, before media were aspirated and replaced with 10%
DMEM supplemented with 0.06 mg/mL geneticin (DMEM-G). Cells
were maintained in DMEM-G; during this time, cell density was
observed to decrease to b1% conﬂuency, and then increase until 80%
conﬂuent. In wild-type (non-transfected) SH-SY5Y cells, incubation in
DMEM-G resulted in 100% cell death. Cells were transferred to a 5 mL
ﬂask, and were maintained in DMEM-G until cells were transferred to
a 75 mL ﬂask, after which point hTH1 and hTH2 SH-SY5Y cells were
routinely maintained in 10% DMEM. TH protein expression was
analyzed using western blotting as described below.
2.5. TH activity assay
Cells were plated in 6-well plates. Cells werewashed in serum-free
media (DMEM supplemented with 10 mM Hepes and 2 mM L-
Glutamine), and then pre-incubated in serum-free media at 37 °C, 5%
CO2 for 2 h. Media were aspirated, cells were washed in phosphate-
buffered saline and 350 μL of homogenization buffer (50 mM Tris, pH
7.5, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 80 μM ammonium
molybdate, 1×protease inhibitor cocktail, 1 mM tetrasodium pyro-
phosphate, 5 mM β-glycerophosphate, 1 mM sodium vanadate and
1 μM microcystin) was added to each well. Wells were scraped, and
cells were lysed by sonication. Samples were centrifuged at 18,000×g
for 15 min at 4 °C, and the supernatants were collected and assayed
for TH activity using a variation of the tritiated-water release assay
[23] as described [14]. Brieﬂy, TH activity assays were initiated by the
addition of an equal volume of reaction mix (60 mM potassium
phosphate buffer, pH 7.4, 0.006% (v/v) 2-mercaptoethanol, 36 μg/mL
catalase, 24 μM tyrosine, 4 μCi L-[3,5-3H]-tyrosine/mL and 20 μM BH4,
ﬁnal concentrations). Background samples did not contain BH4.
Assays were performed at 30 °C for 9 min. Reactions were linear
under these conditions. To determine TH protein levels, SDS-PAGE
and western blotting were performed on cell extracts alongside a
dilution series of recombinant TH calibration standards as described
below.
2.6. Treatment of SH-SY5Y cells
hTH1 SH-SY5Y and hTH2 SH-SY5Y cells were plated in 6- or 12-
well plates. Cells were pre-incubated for 2 h in serum-freemedia prior
to cell treatment as described above. Cells were treated with 10 mM
forskolin, 10 mM muscarine, 50 ng/mL EGF or relative vehicle for
control wells for 5 or 30 min. The vehicle for muscarine and EGF
treatments was H2O, and the vehicle for forskolin was DMSO.
Forskolin and DMSO were added to cells such that the ﬁnal
concentration of DMSO did not exceed 0.1%. For pre-incubation with
UO126, cells were pre-incubated in serum-free DMEM for 1.5 h and
then were incubated with 10 μM UO126 for 30 min.
2.7. Preparation of phospho-speciﬁc antibodies and total TH antibody
To generate antibodies to detect TH phosphorylated at Ser40,
Ser31 or Ser19, we synthesized phospho-peptides corresponding to
residues 36–44 (GRRQpSLIED; pSer40TH), 27–35 (EAVTpSPRFI;
pSer31TH) and 15–23 (RRAVpSEQDA; pSer19TH) of rat TH with the
addition of a terminal cysteine residue as described [24]. After
puriﬁcation by HPLC, an aliquot of each phospho-peptide was linked
to diphtheria toxoid and used to immunize rabbits (for pSer19 and
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serum was collected and antibodies were puriﬁed via phospho-
peptide afﬁnity chromatography. Two milligrams of each phospho-
peptide was coupled to 2 mL of Sulfolink coupling gel using the
Sulfolink immobilization kit for peptides. Serawere puriﬁed according
to the manufacturer's general protocol for afﬁnity puriﬁcation of
protein (Pierce). The speciﬁcity of the phospho-speciﬁc antibodies
was assessed by immunoblotting using recombinant rat TH speciﬁ-
cally phosphorylated to full stoichiometry at Ser40 (by protein kinase
A), Ser31 (by ERK1), Ser19 (mutated form of rat TH (Ser40Ala)
phosphorylated by CaMKII) and also non-phosphorylated recombi-
nant rat TH as described [13]. As shown in Fig. 1A, the phospho-
speciﬁc antibodies recognized their respective phospho-rTH proteins
in a concentration-dependent manner. The phospho-speciﬁc anti-
bodies did not signiﬁcantly cross-react with non-phosphorylated rTH,
or with rTH phosphorylated at the alternative Ser residues. hTH1,
hTH2 and hTH3/4 have different amino acid sequences immediatelyFig. 1. Characterization of phospho-speciﬁc antibodies. (A) The speciﬁcity of phospho-
speciﬁc antibodies was assessed by immunoblotting using different loadings of
recombinant rat TH that was either non-phosphorylated (TH), or phosphorylated
speciﬁcally at Ser40 (pS40), Ser31 (pS31) or Ser19 (Ser40Ala rTH phosphorylated by
CaMKII, pS19). (B) The ability of pSer31 antibody to detect human TH (hTH) isoforms 1,
3 and 4 phosphorylated by ERK (pS31 TH, 150 ng loaded) was assessed by
immunoblotting. (C) pSer31 antibody was incubated without peptide (no pep), or
with pSer35 hTH2, pSer31 TH or pSer40 TH peptides. The binding of the blocked
antibody to pS31 TH (30 and 75 ng loaded) was assessed by immunoblotting. (D)
pSer31 antibody was incubated without peptide, or with 100, 250 or 500 nM of pSer31
TH or pSer35 hTH2 peptides. The binding of the blocked antibody to pS31 TH was
assessed by comparing the densitometric signal from the blocked antibody to that of
the non-blocked antibody. Results are expressed as a percentage of pSer31 antibody
(pS31 Ab) binding blocked by the relative peptides.N-terminal to their relative Ser31 residues. The pSer31 antibody was
therefore further assessed for the detection of the different human TH
isoforms phosphorylated at the equivalent Ser31 residues (Fig. 1B).
The pSer31 antibody recognized recombinant hTH1, hTH3 and hTH4
phosphorylated at the equivalent Ser31 residues by ERK; hTH2 cannot
be phosphorylated by ERK in vitro and thus was not analyzed [11, 13].
To determine if the pSer31 antibody recognizes the pSer35 hTH2
sequence, the pSer31 antibody was incubated for 1 h at 25 °C with
500 nM of pSer35 hTH2 peptide (VRGQpSPRFI), 500 nM pSer31TH
peptide or 500 nM pSer40TH peptide. Both the pSer35 hTH2 peptide
and the pSer31TH peptide were able to block the binding of the
pSer31 antibody to the pSer31 TH immunoblot, while the pSer40TH
peptide did not block binding (Fig. 1C). To further examine the
relative binding of the pSer31 antibody to the pSer35 hTH2 and
pSer31TH peptides, the antibody was incubated with different
concentrations of the two peptides. Both peptides were able to
block the binding of the antibody to the pSer31 TH immunoblot to a
similar extent (Fig. 1D). These data demonstrate that the pSer31
antibody is able to recognize hTH1, 3 and 4 phosphorylated at their
equivalent Ser31 residues despite their different N-terminal amino
acid sequences, and if hTH2 was phosphorylated at Ser35, then the
pSer31 antibody could recognize it.
To generate antibodies to detect non-phosphorylated TH, rabbits
were immunized with recombinant human TH protein lacking the
ﬁrst 156 residues to avoid any interaction of the antibody with the N-
terminal regulatory domain, where phosphorylation could alter the
binding to the antibody to the TH protein. Animals were bled and
serum was collected. Two milligrams of recombinant rat TH was
coupled to Aminolink coupling gel using Aminolink plus immobiliza-
tion kit. Antibodies were puriﬁed according to the manufacturer's
general protocol for afﬁnity puriﬁcation of protein (Pierce). The total
TH antibody recognized recombinant hTH1, hTH2, hTH3 and hTH4 in
a concentration-dependent manner, and recognized each of the 4
isoforms to an equal extent (data not shown).2.8. SDS-PAGE and western blotting
Following incubation of cells with various stimuli, media were
aspirated and treatments were terminated by the addition of Laemlli
sample buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 1% DTT,
2 mM EDTA). Samples were applied to 10% SDS-polyacrylamide gels
before being transferred to nitrocellulose as described [25]. To
determine the stoichiometry of Ser phosphorylation and TH protein
levels, recombinant hTH phosphorylated to full stoichiometry at
Ser19, Ser31 and Ser40 (as described above) was used as a calibration
standard. hTH1 and hTH2 SH-SY5Y cell extracts were run along with a
dilution series of the calibration standards. Nitrocellulose membranes
were then immunoblotted using phospho-speciﬁc or total TH
antibodies as described previously [24], or with anti-β-actin to
provide a protein loading control. Analysis of site-speciﬁc TH
phosphorylation was performed as previously described [14]. Immu-
noblots were visualized using the Image Reader LAS-3000 (Fujiﬁlm)
imaging system using ECL plus detection reagents. The density of total
TH or phospho-speciﬁc TH bands was measured using MultiGauge
V3.0 (Fujiﬁlm).2.9. Statistical analyses
The data were expressed as a fold-increase of the mean of the
control samples (control=1), and are presented as mean ± SEM for
the stated number of experiments. Statistical signiﬁcance was
assessed using one-way ANOVA followed by Tukey's test for multiple
comparisons or Student's unpaired t-tests for analysis of Ser31
phosphorylation and basal phosphorylation stoichiometry.
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3.1. Stable transfection of hTH1 and hTH2 into SH-SY5Y cells
SH-SY5Y cells were stably transfected with hTH1 or hTH2 cDNA
inserted in the pcDNA3.1 mammalian expression vector. The
expression of hTH1 and hTH2 was conﬁrmed by SDS-PAGE and
western blotting, and also by the measurement of TH activity. TH
protein was not observed in wild-type SH-SY5Y cells (Fig. 2A), and
these cells contained no detectable TH activity (Fig. 2B). The absence
of TH from wild-type SH-SY5Y cells is consistent with ﬁndings by
other groups [26].
hTH1 and hTH2 were expressed at similar levels in the transfected
SH-SY5Y cells (Fig. 2A). hTH1 and hTH2 were found to migrate at
approximately 60 kDa. hTH1 and hTH2 can be distinguished as two
different sized bands when the gels are run their entire length
(N10 cm). Similar separation of the two isoforms has previously been
observed [15]. TH activity in the transfected cells was determined to
be 0.23±0.045 and 0.35±0.042 nM DOPA produced/nM TH/min in
hTH1 and hTH2 SH-SY5Y cells, respectively (Fig. 2B, no signiﬁcant
difference, pN0.05). The expression of hTH1 or hTH2 in SH-SY5Y cells
did not change cellular morphology (data not shown).
3.2. In situ phosphorylation of hTH1 and hTH2 at Ser19 and Ser40/44
The hTH1 and hTH2 SH-SY5Y cells were characterized with regard
to the phosphorylation of the three main Ser residues in TH (Ser19,
Ser31 and Ser40 in hTH1; Ser19, Ser35 and Ser44 in hTH2). hTH1 and
hTH2 SH-SY5Y cells were stimulated with 10 μM forskolin for 5 min,
and assayed for phosphorylation and TH protein levels as described in
the Materials and methods section. Stimulation with forskolin
signiﬁcantly increased the phosphorylation of Ser40/44 in both
hTH1 and hTH2 cells (pb0.01, Fig. 3). There was no signiﬁcant
difference in the level of forskolin-induced phosphorylation of Ser40/
44 between hTH1 and hTH2 cells. Ser31 phosphorylation levels were
unchanged in hTH1 (Fig. 3), and phosphorylation of Ser35 was not
detectable in hTH2 in either the control or stimulated cells (data not
shown). Forskolin did not change Ser19 phosphorylation (Fig. 3) or
total TH protein (data not shown) levels in either cell type.
hTH1 and hTH2 SH-SY5Y cells were stimulated with 10 μM
muscarine for 5 min. Muscarine was found to signiﬁcantly increaseFig. 2. Characterization of stably transfected SH-SH5Y cells. (A) Wild-type (wt), hTH1
and hTH2 SH-SY5Y cell extracts were analyzed for TH protein and β-actin content
as described in the Materials and methods section. Results shown are representative.
(B) Wild-type (wt), hTH1 and hTH2 SH-SY5Y cells were lysed and assayed for TH
activity as described in the Materials and methods section. Activity is expressed as nM
DOPA produced/nM TH/min + SEM (n=6).
Fig. 3. Forskolin stimulation of hTH1 and hTH2 SH-SY5Y cells. SH-SY5Y cells were
stimulated with 10 μM foskolin (F) or the same volume of vehicle (C) for 5 min. TH
phosphorylation levels were analyzed and quantiﬁed as described in the Materials and
methods section. Representative pSer40 immunoblot is displayed above relative graph.
Data are presented as the average fold increase relative to mean of control levels + SEM
(n=8 for C, n=5 for F). ⁎pb0.01 vs. corresponding control.the phosphorylation of Ser40/44 in both hTH1 and hTH2 cells
(pb0.001, Fig. 4). Muscarine also induced a substantial increase in
the phosphorylation of Ser19 in both hTH1 and hTH2 cells (pb0.001,
Fig. 4). There was no signiﬁcant difference in the level of muscarine-
induced phosphorylation of Ser19 or Ser40/44 between hTH1 and
hTH2 cells. There was no increase in the phosphorylation of Ser31 in
hTH1 cells (Fig. 4), and again phosphorylation of Ser35 in hTH2 was
not detectable in control or muscarine-stimulated cells (see repre-
sentative immunoblot, Fig. 4). There was no change in TH protein
levels in either cell type (data not shown).
3.3. In situ phosphorylation of Ser31 in hTH1, but not Ser35 in hTH2
hTH1 and hTH2 cells were stimulated with 50 ng/mL EGF for
30 min. EGF signiﬁcantly increased the phosphorylation of Ser31 in
hTH1 (pb0.05, Fig. 5); however, no phosphorylation of Ser35 in hTH2
was detected (see representative immunoblot, Fig. 5). Stimulation
with EGF did not result in any changes in the phosphorylation of
Ser40/44 or Ser19 (Fig. 5), or TH protein levels (data not shown). EGF
Fig. 4. Muscarine stimulation of hTH1 and hTH2 SH-SY5Y cells. SH-SY5Y cells were
stimulated with 10 μMmuscarine (M) or the same volume of vehicle (C) for 5 min. TH
phosphorylation levels were analyzed and quantiﬁed as described in the Materials and
methods section. Representative pSer40/44, pSer31/35 and pSer19 immunoblots are
displayed above relative graphs. Data are presented as the average fold increase relative
to mean of control levels + SEM (n=8 for C, n=5 for M). ⁎⁎pb0.001 vs. corresponding
control.
Fig. 5. EGF stimulation of hTH1 and hTH2 SH-SY5Y cells. SH-SY5Y cells were stimulated
with 50 ng/mL EGF (E) or the same volume of vehicle (C) for 30 min. TH
phosphorylation levels were analyzed and quantiﬁed as described in the Materials
and methods section. Representative pSer31/35 immunoblot is displayed above
relative graph. Data are presented as the average fold increase relative to mean of
control levels + SEM (n=4). ⁎pb0.05 vs. corresponding control.
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(data not shown).
3.4. Basal stoichiometry of serine phosphorylation in hTH1 and hTH2
The basal stoichiometry of serine phosphorylation was assessed
using recombinant hTH standards phosphorylated to full stoichiometry
as described in the Materials and methods section. The basal level of
phosphorylation of hTH1 at Ser40 (0.15 mol phosphate/mol TH
subunit) was signiﬁcantly higher (pb0.05) than Ser44 phosphorylation
in hTH2 (0.09 mol phosphate/mol TH subunit) (Fig 6). However, there
wasno signiﬁcant difference between the basal level of phosphorylation
of Ser19 in hTH1 and hTH2 (0.08 and 0.10 mol phosphate/mol THsubunit). Ser31 phosphorylation stoichiometry in hTH1 was deter-
mined to be 0.04 mol phosphate/mol TH subunit, while basal
phosphorylation of Ser35 in hTH2 was not detectable.
3.5. pSer31-dependent hierarchical phosphorylation contributes to basal
pSer40 levels in hTH1, but not hTH2 cells
We could not detect any phosphorylation of Ser35 in hTH2 under
basal conditions or using stimuli that increased the phosphorylation
of Ser31 in hTH1. Additionally, basal Ser40 phosphorylation stoichi-
ometry was shown to be higher in hTH1 than Ser44 phosphorylation
in hTH2. Phosphorylation of Ser31 can potentiate the phosphorylation
of Ser40 in vitro [13]. We therefore decided to inhibit kinases that are
known to contribute to Ser31 phosphorylation and determine the
effect on Ser40/44 phosphorylation to see if phosphorylation of Ser31
Fig. 6. Basal phosphorylation stoichiometry of hTH1 and hTH2 from SH-SY5Y cells.
Stoichiometry of Ser phosphorylation in untreated cells extracts was determined by
analyzing TH phosphorylation and TH protein levels alongside a series of recombinant
TH standards phosphorylated to full stoichiometry at relative Ser residues. Data are
presented as the average mol phosphate/mol TH subunit + SEM (n=6 for pS40 and
pS19, n=5 for pS31). ⁎pb0.05 for hTH1 vs. hTH2.
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manner. hTH1 and hTH2 SH-SY5Y cells were incubated for 30 min
with 10 μMUO126, which inhibits MEK, a kinase upstream of ERK1/2.
UO126 signiﬁcantly inhibited the phosphorylation of ERK in both
hTH1 and hTH2 cells (pb0.001, Fig. 7). UO126 signiﬁcantly inhibited
basal Ser31 phosphorylation in hTH1 cells (pb0.05, Fig. 7); Ser35
phosphorylation in hTH2 cells was not detectable (data not shown).
UO126 also signiﬁcantly inhibited the basal phosphorylation of Ser40
in hTH1 (pb0.05), but did not inhibit the phosphorylation of Ser44 in
hTH2 (Fig. 7). Ser19 phosphorylation levels and total TH levels were
not signiﬁcantly decreased following treatment with UO126. These
data indicate that phosphorylation of Ser31 can contribute to Ser40
phosphorylation in hTH1; however, this effect is absent in hTH2 cells
due to the lack of Ser35 phosphorylation.Fig. 7. UO126 treatment of hTH1 and hTH2 SH-SY5Y cells. SH-SY5Y cells were pre-incubated
ERK (pERK) and TH phosphorylation levels were analyzed and quantiﬁed as described in the
to mean of control levels + SEM (n=5, n=6 for pERK). ⁎pb0.05 vs. corresponding contro4. Discussion
Phosphorylation of Ser31 plays an important role in the regulation
of hTH1, primarily by its effect on the potentiation of Ser40
phosphorylation. However, there has been no kinase identiﬁed that
is capable of phosphorylating hTH2 at Ser35 in vitro. In this study, we
have demonstrated that while basal phosphorylation of Ser40 in hTH1
is potentiated by the phosphorylation of Ser31 in situ, hTH2 is not
subject to the same regulatory mechanism. In addition, we have
demonstrated using stimuli that induce a large increase in Ser31
phosphorylation in hTH1, and also under conditions that increase
intracellular Ca2+ mobilization, that there is no detectable phosphor-
ylation of Ser35 in hTH2. This represents a fundamental difference
between the regulatory mechanisms utilized by the major human TH
isoforms.
To date, there have been no studies that have investigated the
different phosphorylation proﬁles of hTH1 and hTH2 in situ. hTH1 and
hTH2 were stably expressed in SH-SY5Y cells, a neuroblastoma cell
line with a dopaminergic phenotype. Stimulation with forskolin
induces a selective increase in the phosphorylation of Ser40/44 in
hTH1 and hTH2 cells. Stimulation of hTH1 and hTH2 cells with
muscarine results in an increase in the phosphorylation of both Ser19
and Ser40/44. This correlates with in vitro data demonstrating that
the two major hTH isoforms are phosphorylated to an equal extent at
Ser19 and Ser40/44 [11,27].
Stimulation of hTH1 cells with EGF resulted in a substantial
increase in the phosphorylation of Ser31, which was not accompanied
by an increase in Ser40 phosphorylation. It was expected that
phosphorylation of Ser31 would potentiate the phosphorylation of
Ser40. However, in the transfected SH-SY5Y cells, forskolin only
induced a mild (1.6-fold) increase in the phosphorylation of Ser40,with 10 μM UO126 (UO) or the same volume of vehicle (C) for 30 min. Phosphorylated
Materials and methods section. Data are presented as the average fold increase relative
l, ⁎⁎pb0.001 vs. corresponding control.
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induced increase in Ser40 phosphorylation that was previously found
in bovine adrenal chromafﬁn cells [13,14]. To further examine this, the
stoichiometry of basal phosphorylation levels of all three Ser residues
was determined. It was shown that the basal phosphorylation of Ser40
was signiﬁcantly higher than basal phosphorylation of Ser44 in hTH2.
In addition, the basal phosphorylation levels of both Ser40 and Ser44
in hTH1 and hTH2, respectively, were 3–5-fold higher than the basal
phosphorylation of Ser40 in chromafﬁn cells [14], and also higher than
the basal Ser40 phosphorylation in PC12 cells [28,29]. However, the
basal phosphorylation of Ser19 was similar in hTH1 and hTH2 cells,
andwas similar to that previously determined in chromafﬁn and PC12
cells [14,28,29]. The basal phosphorylation stoichiometry of Ser31 in
hTH1 was also found to be similar to that determined previously in
chromafﬁn cells [13]. When viewed together, this may mean that
there is a higher basal level of Ser40/Ser44 kinase activity in the
transfected SH-SY5Y cells, and could explain why phosphorylation of
Ser31 alone could not further increase Ser40 phosphorylation. In
effect, we may have already exceeded the level of Ser40 phosphor-
ylation that can be altered by hierarchical phosphorylation via Ser31.
As previously noted, there is a signiﬁcantly higher level of basal
phosphorylation of Ser40 in hTH1 than Ser44 in hTH2. To examine
whether Ser31 phosphorylation was contributing to the higher level
of basal phosphorylation of Ser40 in hTH1 in situ, we treated the cells
with UO126 which signiﬁcantly inhibited the phosphorylation of ERK
in both hTH1 and hTH2 cells, and resulted in a 50% inhibition of Ser31
phosphorylation in hTH1. Importantly, there was a 50% inhibition of
Ser40 phosphorylation in hTH1 that was not accompanied by a
concomitant inhibition of Ser44 phosphorylation in hTH2. The
inhibition of Ser40 phosphorylation in hTH1 cells must be due to an
UO126-mediated inhibition of Ser31 phosphorylation; if UO126 was
acting upstream of the Ser40 kinase pathway, then a decrease in
phosphorylation of Ser40/44 would be present in both cell types.
Therefore, we have demonstrated that while hTH1 is regulated by
Ser31-mediated hierarchical phosphorylation of Ser40 under basal
conditions in situ, hTH2 is not subject to this form of regulation.
While EGF induced a substantial increase in the phosphorylation of
Ser31 in hTH1, it did not increase the phosphorylation of Ser35 in
hTH2. Activation of themuscarinic receptor results in themobilization
of Ca2+ from intracellular stores and activation of Ca2+-dependent
kinases such as CaMKII [30,31]. Muscarine potently increased the
phosphorylation of Ser19 and Ser40/44 in both hTH1 and hTH2,
which is consistent with the activation of Ca2+-dependent kinases;
however, stimulation with muscarine for 5 min (Fig. 5) or 30 min
(data not shown) was not able to increase Ser31/35 phosphorylation
in hTH1 or hTH2 cells. Therefore, using a range of stimuli that activate
a variety of intracellular signaling pathways, we have not detected
Ser35 phosphorylation in hTH2 in situ. This correlates with in vitro
data, where there has been no kinase identiﬁed that is capable of
reproducibly phosphorylating hTH2 at Ser35. It is likely that the 4
amino acid substitution in hTH2 is altering the ability of kinases to
recognize and phosphorylate the Ser35 residue.
This is the ﬁrst study to demonstrate that hTH1 and hTH2 are
differentially regulated in situ. The lack of phosphorylation of Ser35 in
hTH2 in situ means that Ser35 is not able to facilitate the hierarchical
phosphorylation of Ser44. Haycock and colleagues have demonstrated
that the human TH isoforms may be differentially distributed in
different cell populations. For example, in dopaminergic cells of the
substantia nigra, it was shown that although all four human TH
isoforms were expressed in the cell body, hTH1 was selectively
distributed along the axons and terminal ﬁelds of these neurons [20].
The selective targeting of the isoformswould provide amechanism for
the region-speciﬁc modulation of TH activity. hTH1 and hTH2 are
subject to differential regulation, and therefore the rate of catechol-
amine synthesis that occurs at speciﬁc cellular regions would depend
on the relative amounts of the isoforms that are present in that region.Therefore, the differential regulation of the major human TH isoforms
may have important consequences for the control over catecholamine
biosynthesis in vivo.Acknowledgments
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